Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass  by Prondzinsky, Roland et al.
CSPCardiopulmonary
Support and
PhysiologySurgical trauma affects the proinflammatory status after cardiac
surgery to a higher degree than cardiopulmonary bypass
Roland Prondzinsky, MD,a Axel Knüpfer, MD,a Harald Loppnow, PhD,a Frank Redling, MD,b Dirk W. Lehmann, MD,c
Ina Stabenow, MD,a Rochus Witthaut, MD,a Susanne Unverzagt, PhD,d Joachim Radke, MD,cHans-Reinhard Zerkowski, MD,b and Karl Werdan, MDaFrom the Department of Medicine III,a De-
partment of Cardiothoracic Surgery,b De-
partment of Anesthesiology,c and Operative
Intensive Care Medicine und Coordination
Centre for Clinical Trials,d Martin-Luther-
University Halle-Wittenberg, Halle (Saale),
Germany.
This study was supported by grant
BMBF-06 of the German government to H.
Loppnow and K. Werdan, and by an unre-
stricted grant from Guidant Corporation to
R. Prondzinsky and K. Werdan.
Received Dec. 1, 2003; revisions received
June 7, 2004; accepted for publication July
6, 2004.
Address for reprints: Roland Prondzinsky,
MD, Martin-Luther-University Halle-Witten-
berg, Department of Internal Medicine III,
Ernst-Grube-Str 40, D-06097 Halle (Saale),
Germany (E-mail: roland.prondzinsky@
medizin.uni-halle.de).
J Thorac Cardiovasc Surg 2005;129:760–6
0022-5223/$30.00
Copyright © 2005 by The American Asso-
ciation for Thoracic Surgery
Dr Prondzinskydoi:10.1016/j.jtcvs.2004.07.052
760 The Journal of Thoracic and CardioObjectives: Cytokines contribute to the development of the systemic inflammatory
response syndrome or multiple-organ failure frequently observed after cardiopul-
monary bypass–supported cardiac surgery. To quantify the contribution of bypass-
induced versus trauma-induced inflammatory response after coronary artery bypass
grafting, we examined plasma cytokine levels in 120 patients with coronary artery
disease who were treated with or without cardiopulmonary bypass–assisted procedures.
Methods: Patients were treated in accordance with one of the following protocols:
(1) elective percutaneous coronary intervention without cardiopulmonary bypass (n
 69), (2) cardiopulmonary bypass–supported percutaneous coronary intervention
(cardiopulmonary bypass–percutaneous coronary intervention; n  10), and (3)
cardiopulmonary bypass–supported coronary artery bypass grafting (cardiopulmo-
nary bypass–coronary artery bypass grafting; n  41). Cytokine levels (picograms/
milliliter) were measured by enzyme-linked immunosorbent assay from plasma
samples obtained at various time points.
Results: Interleukin-6 was measured in blood samples from all 3 patient popula-
tions. The maximum interleukin-6 level was 13.6 22.3 pg/mL in the percutaneous
coronary intervention group, 170.4  165.4 pg/mL in the cardiopulmonary bypass-
percutaneous coronary intervention group, and 640.3  285.7 pg/mL in the cardio-
pulmonary bypass-coronary artery bypass grafting group. Interleukin-6 levels were
significantly different, and the 95% confidence intervals did not overlap. In the
cardiopulmonary bypass-percutaneous coronary intervention group, bypass duration
correlated well with interleukin-6 production (r  0.915; P  .001), whereas these
parameters did not correlate in patients who underwent cardiopulmonary bypass–
coronary artery bypass grafting (r  0.307; P  .054).
Conclusions: These findings support the suggestion that surgical trauma and car-
diopulmonary bypass contribute to the inflammatory response after cardiac surgery,
although trauma may contribute to a higher degree.
Organ dysfunction after cardiac surgery is mainly attributed tothe systemic inflammatory response syndrome (SIRS). Cyto-kines are released after surgical trauma or when blood isexposed to artificial surfaces during cardiopulmonary bypass(CPB). In addition to other factors, high levels of cytokinesmay contribute to postoperative complications such as SIRS
and multiple organ failure.1 Cytokine plasma levels peak within hours after
vascular Surgery ● April 2005
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Ptermination of CPB and decrease to preoperative levels
after 24 hours.2 Patients with severely impaired preoper-
ative left ventricular function and complicated postoper-
ative courses after cardiac surgery3 express higher inter-
leukin-6 (IL-6) levels4 and higher tumor necrosis
factor- (TNF- ) and TNF receptor (RI and RII) levels.5
However, it remains to be shown whether the increased
inflammatory response, for which increased plasma IL-6
levels after CPB-supported major cardiac surgery are
indicative, is predominantly induced by the operative
trauma, including thoracotomy, or results from the acti-
vation of blood after contact with the artificial surfaces of
the extracorporeal circuit or the mechanical stress exerted
by it. In addition to alternative approaches,6,7 interest has
focused on minimally invasive revascularization strate-
gies with mini-thoracotomies and CPB, or even without
CPB, as well as different revascularization techniques
(eg, CPB-percutaneous coronary intervention [PCI] or
conventional PCI). The latter strategies offer interesting
therapeutic perspectives for the vast number of patients
who require cardiac revascularization. Such strategies
reduce the risk of an escalating postprocedural SIRS.
This study was designed to distinguish the contribution
of CPB from that of surgical trauma to the increase of
inflammatory mediators after cardiac surgery. Because IL-6
levels were much higher in patients undergoing cardiac
surgery supported by CPB than in those patients who un-
derwent bypass-supported PCI, we conclude that both CPB
and surgical trauma contribute to the observed inflammatory
response. Surgical trauma of conventional surgical proce-
dures, however, is a more potent activator of the inflamma-
tory response after cardiac surgery than CPB.
Patients and Methods
Patients
This prospective study was approved by the local ethics committee
and carried out from 1995 to 1997. After giving their written
informed consent, 120 patients were included. Coronary artery
disease was diagnosed in all patients, for which they were treated.
After diagnostic heart catheterization, patients were assigned to 1
of 3 groups according to the clinical criteria outlined in Table 1.
The CPB-PCI group included patients who were not eligible for
coronary artery bypass grafting and in whom unsupported PCI was
expected to present an unacceptable risk. Criteria for CPB-PCI
included poor left ventricular function or 50% or more of jeopar-
dized myocardium close to the targeted vessel, following the
definitions used by the “National Registry for Supported Angio-
plasty.”8
All CPB procedures were performed under standard general
anesthesia: midazolam, pancuronium, and fentanyl were used
for induction. Anesthesia was maintained by isoflurane inhala-
tion. The activated clotting time (ACT) was maintained at or
above 400 seconds by appropriate heparin doses. During CPB,
perfusion pressure was maintained at 50 to 70 mm Hg. Open
circuits with combined venous and cardiotomy reservoirs were
The Journal of Thoraciused in both CPB groups. Each system included a roller pump,
hollow-fiber membrane oxygenator with integrated heat ex-
changer, and arterial blood filter. All circuits were uncoated.
The CPB priming solution (1751 mL: 850 mL Thomaejonin
electrolyte prime, 500 mL hydroxyethyl starch 6%, 250 mL
mannitol M15, 50 mL NaHCO3, 100 mL aprotinin, and 1 mL
heparin) contained 5000 IU of heparin. Both CPB groups were
treated with the same standard intravenous heparinization reg-
imen: 350 IU/kg body weight before cannulation and ACT
check 5 minutes later (aiming for 400 seconds). If the ACT was
lower, an extra third of the initial heparin dose was adminis-
tered. After weaning from CPB, patients were given protamine
to neutralize the heparin. Heparin antagonization was identical
in both groups.
In patients undergoing CABG, myocardial protection was per-
formed by antegrade infusion of Bretschneider solution. For ino-
tropic support, epinephrine and enoximone were used as first-line
drugs. In the CPB-PCI group, arterial (16F) and venous (18F)
cannulas were percutaneously placed in the respective femoral
vessels. All CPB procedures were performed under normothermic
conditions. Unsupported PCI was performed by the Judkins tech-
nique through the femoral artery using conventional (7F) guiding
catheters and 0.014-inch guide wires. For coronary angioplasty,
2.5- to 3.5-mm balloon catheters were used.
Determination of Cytokine Levels
Blood samples were obtained before the respective intervention as
well as 1, 2, 3, 6, 24, 48, 72, 96, and 120 hours after starting each
procedure. Samples were centrifuged, and the plasma was stored at
80°C. Cytokine measurements were performed with commercial
enzyme-linked immunosorbent assay kits (IL-6 OPTEIA, Pharm-
ingen, Heidelberg, Germany; IL-1ra, IL-8, Biosource, Hamburg,
Germany; IL-1, IL-6, IL-10, TNF, TNF RI, and RII, Roche
Diagnostics GmbH, Mannheim, Germany; sCD14: IBL, Hamburg,
Germany; IL-1: R&D Systems, Wiesbaden, Germany) in accor-
dance with the manufacturers’ recommendations.
Statistical Analysis
Statistical analysis was performed by using SPSS (SPSS Inc,
Chicago, Ill) for descriptive statistics and analysis of variance.
Changes of IL-6 serum levels were prospectively defined as the
end points of the study. The relationship between the IL-6 level on
the first day posttreatment and the type of management protocol
was assessed in 69 patients who underwent PCI, in 10 patients
after CPB-PCI, and in 41 patients after CABG (Table 1). The
analysis focused on the 2- to 24-hour time period to avoid an
observational bias caused by missing data of earlier or later time
points. The statistical analysis included analysis of variance, risk
score ranging, Pearson’s correlation, multiple Sidak adjusted com-
parisons for global probability, and the Dunnett C test for unequal
variances.
To avoid systematic errors when calculating maxima, the base-
line value (preprocedure sample) was subtracted from the level
reached at each subsequent sampling time. The peak value was
then determined as indicated in formula 1:Formula 1:
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CSPMaxIL-6  Max (IL-6 ⁄ 2 hours baseline IL-6;
IL-6 ⁄ 3 hours baseline IL-6;
IL-6 ⁄ 6 hours baseline IL-6;
or IL-6 ⁄ 24 hours baseline IL-6)
Analysis of variance requires that the IL-6 level increase is
normally distributed with comparable variances among the 3 treat-
ment groups. However, the data were not normally distributed, but
showed a steep left-sided slope. Therefore, a sensitivity analysis
investigating the influence of the steep left-sided slope and differ-
ent variances was performed. The analysis showed that neither
resulted in the loss of significance of the differences in IL-6
production among the 3 treatment groups.
A basal increase of the IL-6 level can be the result of various
preclinical parameters. The conditions described by the preproce-
dural APACHE-II score or the parameters of the risk score de-
TABLE 1. Patient data: Clinical, angiographic, and proced
No. of patients
Demographic data
Age (y)
Sex (male/female)
Preprocedural data
Coronary artery disease (1/2/3 vessel disease)
Previous angioplasty
Previous CABG
Heart failure (NYHA)
Angina pectoris (CCS)
Diabetes
Ejection fraction (%)
APACHE-II (preprocedural)
Risk score 1.
Medication‡
Acetylsalicylic acid
Ticolopidine
Clopidogrel
Abciximab
Tirofiban
Eptifibatide
Procedural data
Systemic heparinization§
Preoperational
1. Postprocedural day
2. Postprocedural day
3. Postprocedural day
CPB duration (min)
CPB mean flow (L/min)
Stents
PCI, Percutaneous coronary intervention; CPB, cardiopulmonary bypass; C
Canadian Cardiovascular Society.
*Number of patients with missing data.
†Treatment day of missing data.
‡Yes/no.
§Intravenous/subcutaneous.scribed next (formula 2), including diabetes (DM), ejection frac-
762 The Journal of Thoracic and Cardiovascular Surgery ● Aprition (EF), and severity of coronary artery disease (CAD; all 3
presented in Table 1), may be of major importance for the prepro-
cedural IL-6 plasma level. Thus, the latter 3 variables were in-
cluded in the risk score. The sum of the risk score can range from
0 (risk not increased) to 3 (very high risk). For the analysis of
variance, the baseline conditions were treated as covariates.
Formula 2:
risk score sum_DM sum_EF sum_CAD
sum_DM 1 if diabetic0 if not diabetic
sum_EF
1 if EF 50
70
20

1
20
EF if 50EF 70
characteristics
PCI CPB-PCI CPB-CABG
69 10 41
.8 9.0 58.0  7.3 63.7 8.9
53/17 7/1 36/5
2/21 (5)* 2/3/5 1/13/27
28 2 3
1 6 0
0 0.88 2.67  0.71 2.34 0.76
7 0.7 2.67 1.1 2.51 0.8
/44 (1)* 5/5 12/29
13.0 (2)* 45.0 19.4 57.1 17.6 (1)*
1.9 (4)* 11.8 2.3 (4)* 5.8 2.3
0.78 (5,* 1†) 1.90 0.67 1.62 0.79 (1)*
66/3 70 (3)* 37/4
/48 (6)* 4/2 (4)* 0/41
/64 (5)* 0/7 (3)* 0/41
/63 (5)* 0/7 (3)* 0/41
/64 (5)* 0/7 (3)* 0/41
/64 (5)* 0/7 (3)* 0/41
69/0 10/0 41/0
14/55 7/3 38/3
3/66 2/8 18/23
10/59 1/5 (4)* 11/30
— 82.9 31.0 56.3 30.2
— 2.35 0.4 4.60 0.4
11 6 —
coronary artery bypass grafting; NYHA, New York Heart Association; CCS,ural
58
21/2
2.2
1.8
24
63.1
5.0
29
15
0
1
0
0
ABG,
0 if EF 70
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Psum_CAD 
1 if CAD 3
0.5 if CAD 2
0 if CAD 1
Both factors (APACHE-II score and risk score) were taken into
account because both reflect the patients’ overall pretreatment
condition. The factors were not correlated with each other (Pearson
correlation: r  0.167; P  .073).
Differences between treatment modalities and their relationship
to IL-6 release were assessed by variance analysis. The model took
the influence of the treatment method on IL-6 increase into ac-
count. Pretreatment risk (risk score according to formula 2) and
preprocedure APACHE-II score were considered to be covariates.
Differences between the treatment methods were also evaluated by
using multiple Sidak adjusted comparisons for a global probability
of an error of 5%. Furthermore, the influence of the different
variances and the steep left-sided slope were investigated by
additional analyses of variance.
Results
High-Risk CPB-Supported Patients Undergoing
Percutaneous Coronary Intervention Express Elevated
Levels of Various Cytokines
To study the role of cytokines in the inflammatory response
to cardiac surgery supported by CPB, we first investigated
the expression of various cytokines in 3 selected high-risk
patients undergoing CPB-PCI. Cytokine levels were deter-
mined in samples taken at various time points: before sur-
gery (0), immediately after starting the procedure, and up to
120 hours postoperatively. Among the cytokines tested,
IL-1 and IL-1 were not detectable, and neither IL-8 nor
IL-6 TNF RIsCD14
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Figure 1. Increased levels of various cytokines in car
percutaneous coronary intervention (PCI) (CPB-PCI). P
(marked by 3 different symbols) of interleukin (IL)-6, so
type 1 (RI) and type 2 (RII), IL-1 receptor antagonist (IL
at various time points. The cytokine levels are given in p
were as follows: IL-6, 70 pg/mL; sCD14, 8000 pg/mL; TN
IL-10, 700 pg/mL). Note the broken scale in the IL-1raTNF was elevated throughout the investigational period
The Journal of Thoraci(data not shown). Plasma levels of IL-6, IL-1 receptor
antagonist (IL-1ra), IL-10, soluble TNF receptor types 1 and
2, and soluble CD14 were elevated (Figure 1). Because the
role of TNF receptors and sCD14 is still controversial, and
IL-1ra and IL-10 levels showed marked variations between
patients, we used IL-6 as an accepted marker for the inflam-
matory response in the subsequent investigation.
Interleukin-6 Levels in High-Risk, CPB-Supported
Patients Undergoing Percutaneous Coronary
Intervention Are Lower than in Bypass-Supported
Patients Undergoing CABG
To investigate to what extent CPB contributes to the inflam-
matory response after cardiac surgery, we compared the
release of IL-6 during and after conventional PCI, CPB-
PCI, and CPB-CABG. Patients undergoing PCI produced
only very low levels of IL-6 during the whole time course of
the investigation. In these patients, the IL-6 mean peak
plasma level (MaxIL-6) (Figure 2) defined between 2 and 24
hours was 13.6  22.3 pg/mL. In contrast, patients under-
going CPB-PCI produced more IL-6 (170.4  165.4 pg/
mL). Patients undergoing CPB-CABG experienced CPB
under conditions qualitatively comparable with those of
patients undergoing CPB-percutaneous transluminal coro-
nary angioplasty, but instead of PCI, patients undergoing
CPB-CABG were subjected to conventional major cardiac
surgery. In these patients, the MaxIL-6 was 640.3  285.7
pg/mL.
IL-6 levels may be influenced by various baseline con-
TNF RII IL-1ra IL-10
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CSPscore. In the CPB-PCI group, both scores were unfavorable
compared with PCI and CPB-CABG (Table 1) and were
therefore entered as covariates. Variance analysis revealed
that 75% of the IL-6 level changes result from a combina-
tion of the specific type of treatment, the APACHE-II, and
the risk score. Analysis of variance also showed that the
increase of the IL-6 level was significantly related to the
particular type of treatment (P  .001), whereas the initial
conditions did not have a significant impact (APACHE-II, P
 .274; risk score, P  .164). All differences between the
3 treatment groups were validated by pairwise multiple
comparison (Sidak correction, Dunnett C test for unequal
variances; P values  .026). The differences between treat-
ment groups were significant (compare Figure 2). The lack
of overlap between the confidence intervals, presented in the
legend to Figure 2, supports the suggestion that these dif-
ferences are significant. The differences are not affected by
logarithmic transformation of the data or by adding the
CPB-PCI
0
200
400
600
800
1000
CPB-CABGPCI
0.026 < 0.001
< 0.001
P
la
sm
a 
IL
-6
 (
pg
/m
l)
Figure 2. IL-6 plasma levels in patients undergoing PCI, CPB-PCI,
or CPB-CABG are significantly different. Plasma was taken from
patients of the 3 groups at various time points after the surgical
procedure was started. IL-6 was measured by enzyme-linked
immunosorbent assay. The preoperative level was subtracted,
maximal IL-6 release (MaxIL-6) in the 2- to 24-hour period was
determined, and a box plot analysis was performed. The circle in
the box reflects the mean (MaxIL-6; PCI 13.6  22.3 pg/mL; CPB-
PCI, 170.4  165.4 pg/mL; CPB-CABG, 640.3  285.7 pg/mL) of the
data, and the dotted line reflects the median. The lines above and
below the box provide the 75th and 25th percentiles, respectively.
The whiskers above and below show the 90th and the 10th
percentiles, respectively. The P values obtained by Sidak confor-
mation are presented. Ninety-five percent confidence intervals
were 28.0 and 55.2 for PCI; 61.1 and 279.6 for CPB-PCI; and 586.4
and 694.1 for CPB-CABG.covariates. On the other hand, different baseline conditions
764 The Journal of Thoracic and Cardiovascular Surgery ● Apripresent in the groups investigated in this study may disguise
the influence of the type of treatment, although the treatment
may have a significant impact. The impact of the baseline
data interferes with the level of significance, the influence of
the type of procedure, and the role of CPB on IL-6 release.
However, the influence of the initial conditions, reflected by
the pretreatment risk score and the APACHE-II score, on
IL-6 release remained insignificant.
The data indicated a higher contribution of the surgical
trauma to elevated IL-6 levels in patients undergoing CPB-
CABG, compared with the effects of CPB. This suggestion
is further supported by the observation that, compared with
the CPB-CABG group, CPB duration is significantly higher
(Mann-Whitney U test: P  .004; Table 1) in patients
undergoing CPB-PCI and by analyzing the correlation of
the bypass duration to maximal IL-6 levels. The latter
analysis showed a correlation in the CPB-PCI group (r 
0.915, P  .001), whereas the correlation was low in the
CPB-CABG group (r  0.307) and not significant (P 
.054), indicating that IL-6 levels depend more on CPB
duration in patients undergoing CPB-PCI compared with
CPB-CABG (Figure 3). On the other hand, there was no
detectable correlation between mean flow rates (r  0.067)
or peak flow rates (r  0.164) and the maximal IL-6 levels
in patients undergoing CPB-CABG or CPB-PCI (r  0.454
Figure 3. Correlation between CPB duration and MaxIL-6 is lower
in the CPB-CABG group than in the CPB-PCI group. The IL-6
release of each individual patient was measured in the 2- to
24-hour time period. MaxIL-6 was determined for this period
(Figure 2), and the data were correlated to the duration of the
CPB. The correlation of the CPB-PCI (filled circles) was r  0.915
(P < .001), and the correlation of the CPB-CABG (open circles)
was r 0.307 (r 0.054). The outlier (filled triangle) was removed
from the CPB-PCI calculation, because outlier analysis showed
that the value was out of the 3S area.or 0.425, respectively).
l 2005
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PDiscussion
Cytokines are important modulators of immune functions,
infectious processes, and the inflammatory response.9 Re-
cent interest has focused on the role of cytokines in cardiac
surgery, particularly CPB-supported surgery. In comparison
with other heart diseases, little is known about cytokine
release in patients who develop postoperative complications
after cardiac surgery.10 So far, it has not been possible to
distinguish between the role of surgical trauma versus CPB
on cytokine production after cardiac surgery. We provide
evidence that in patients undergoing CPB-CABG, the sur-
gical procedure itself is a more potent activator of the
proinflammatory response than CPB.
Elevated levels of cytokines have been observed in pa-
tients who underwent CPB-supported surgery.11-13 Severe
inflammatory response to CPB-supported cardiac surgery is
thought to be mediated by cytokines involved in the regu-
lation of inflammation, such as IL-6 or TNF. However, the
role and expression of cytokines in high-risk patients with
cardiac disease who undergo PCI supported by normother-
mic CPB are not well understood. Thus, we first investi-
gated the expression of important proinflammatory and anti-
inflammatory cytokines in 3 selected high-risk patients
undergoing CPB-PCI. Among the cytokines tested, plasma
levels of TNF, IL-1, IL-1, and IL-8 were not above
baseline in these patients. Likewise, our previous reports
regarding TNF expression after cardiac surgery have shown
that postoperative TNF levels are not increased in patients
with low APACHE-II scores.5 This is consistent with the
present results, because the APACHE-II score of patients
investigated here was below 19. We have also reported5 that
patients with APACHE-II scores greater than 24 expressed
considerably elevated TNF levels, and that TNF and TNF
receptor levels could be used to predict adverse outcome.
On the other hand, data regarding TNF during cardiac
surgery are conflicting,14 with TNF- reported to be present
in chronic heart failure and cachexia,15,16 as well as during
and after CPB, paralleled by elevated levels of endotoxin.17
The role of IL-1 in cardiovascular diseases has not been
investigated in great detail.18,19 However, IL-1 is present in
the plasma of patients with myocarditis,20 but not in those
with myocardial infarction21 or chronic heart failure.22
From the various cytokines tested, we chose IL-6 as a
marker of the inflammatory response in all 3 patient groups.
Increased IL-6 levels have been proposed as a prognostic
proinflammatory marker, for example, in heart failure23 and
after cardiac surgery with CPB support.24 Our data show
that the maximal IL-6 levels observed during the first post-
operative 24 hours were significantly higher in patients
undergoing CPB-CABG compared with PCI and CPB-PCI.
These results are consistent with recent publications show-
ing that procedures without CPB support (“off-pump pro-
cedures”) minimized surgical trauma, other than the CPB-
The Journal of ThoraciPCI techniques used in this work, and decreased the severity
of the postoperative SIRS.25-28
Our data extend the mentioned literature findings by
providing evidence that in patients undergoing CPB-CABG,
trauma contributes more potently to IL-6 release than ex-
tracorporeal circulation. This conclusion is supported by 2
lines of evidence. First, we show that the maximum IL-6
release in patients undergoing CPB-PCI is much lower than
in patients undergoing CPB-CABG. In patients undergoing
CPB-PCI, most of the IL-6 release is probably induced by
CPB, because only very small amounts of IL-6 are detect-
able in patients undergoing PCI without CPB. Assuming a
comparable effect of CPB in patients undergoing CPB-
CABG or CPB-PCI, trauma must be the major IL-6 inducer
in patients undergoing CPB-CABG: After correction for the
IL-6 level observed in patients undergoing PCI (13.6 pg/
mL), the contribution of the CPB (156.8 pg/mL), as deter-
mined in patients undergoing CPB-PCI, counts for only one
quarter of the IL-6 (626.7 pg/mL) measured in patients
undergoing CPB-CABG. The remaining 75% of the IL-6
(626.7-156.8  469.9 pg/mL) may be caused by the trauma
and additional factors. Second, the present data show a
statistically significant correlation (P  .001) of CPB du-
ration and IL-6 release (r  0.915) in patients undergoing
CPB-PCI. However, in patients undergoing CPB-CABG,
the correlation between bypass duration and IL-6 peak
levels is low (r  0.307) and not significant (P  .054). It
remained insignificant (P  .095), even if the outlier was
included in the calculation of the correlation.
Conclusions from these results may be limited because
of the relatively small patient numbers in the CPB-PCI
group. Nevertheless, we believe that the weak correlation
between IL-6 release and CPB duration in patients under-
going CPB-CABG (in comparison with CPB-PCI patients)
indicates trauma (vs extracorporeal circulation) as a cause
of higher and more variable IL-6 release.
With respect to the statistical analysis, the small number
of patients in the CPB-PCI group presents a particular
problem, especially because of the nonrandomized charac-
ter of the study. For ethical and legal reasons, however,
randomization would not have been acceptable at any time.
In addition, inclusion of a CPB-PCI patient group was a
unique chance from a historical perspective, because this
treatment strategy is no longer indicated or has only rare
indications. In view of the markedly improved options pro-
vided by catheter interventions, including clearly safer and
less-complicated stent insertion and the use of GP-IIb/IIIa
antagonists supplemented by intraaortic balloon pumping,
CPB-PCI can no longer be justified today.
Current data29 are inconclusive as to which patient group
derives the most benefit from off-pump coronary revascu-
larization. Reduced inflammatory response, that is, initial
benefit of avoiding CPB, has to be weighed against de-
c and Cardiovascular Surgery ● Volume 129, Number 4 765
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CSPcreased 3-month graft patency rates. Conceivably, the ben-
efit will be highest in elderly patients in whom preoperative
comorbidities are more frequent and who are subsequently
expected to have a higher perioperative risk of organ failure.
In summary, the present data show that both CPB and the
surgical procedure itself strongly contribute to the induction
of IL-6 release during cardiac surgery. However, the con-
tribution of trauma, compared with CPB, is much higher in
CPB-assisted cardiac surgery.
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